Anti-Vaxx Holocaust: Louisiana hospitals, overwhelmed with Covid patients, sending ambulances to Texas

State’s public health efforts hobbled by low vaccination rates and crowded housing following last year’s hurricane season

4
1154

Guardian: Like so many people in Louisiana, Tyler Duplantis was hesitant to get a Covid-19 vaccine.

The 26-year-old witnessed the virus tear through his Native American tribe, the United Houma Nation, last year. But when the vaccine became available to him, he was skeptical for several reasons.

There were the stories he’d read on social media, the comments his peers made and then there was the intergenerational trauma provoked by mistreatment of Native American people by the US government. “The healthcare system has betrayed minority populations in the past,” he said.

Duplantis confronted his skepticism by talking to doctors and nurses he knew, who explained that the vaccines available to fight Covid-19 are both safe and effective. “Once I started asking those questions and getting the answers, I felt more comfortable,” he said. He is now among the nearly 38% of Louisiana residents who are fully vaccinated.

But, amid a brutal spike in infections, it is clear Louisiana needs more people like Duplantis, willing to change their mind and get vaccinated as the Delta variant of the virus sweeps through the state and fills ICU units, in scenes reminiscent of the worst days of the pandemic last year.

Louisiana now has the second highest rate of new infections in the nation, after Florida. And its low rate of vaccination means that more of the coronavirus cases are requiring hospitalisation. About 90% of current coronavirus patients in Louisiana hospitals are not fully vaccinated, according to the state’s department of health. As the Delta variant spreads rapidly through unvaccinated communities, Covid-positive patients are overwhelming Louisiana’s healthcare system.  read more..

https://www.theguardian.com/us-news/2021/aug/13/covid-19-louisiana-hospitals-low-vaccination-rates

 

 

About VT Editors
VT Editors is a General Posting account managed by Jim W. Dean and Gordon Duff. All content herein is owned and copyrighted by Jim W. Dean and Gordon Duff
ATTENTION READERS
Due to the nature of independent content, VT cannot guarantee content validity.
We ask you to Read Our Content Policy so a clear comprehension of VT's independent non-censored media is understood and given its proper place in the world of news, opinion and media.

All content is owned by author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.

About VT - Read Full Policy Notice - Comment Policy

4 COMMENTS

  1. Here is another possible treatment for coved 19. Along with Ivermectin and other FDA approved drugs, we need some rational treatments now that we see breakthrough infections like the delta varient (coved varients that ARE infecting the vacinated.) I believe that the vacines are our best defense, but if one becomes infected with it and like me, they are vacinated, what are they to do… There is no treatment regime that I know of which all agree hands down is the best. In fact, from what I read, they mostly treat the symptom’s and try to do what they can to be sure the patient gets enough oxygen. Some institutions seem to have found steroids that mitigate the damage to the lung tissue by the cytokine storm. But it would be best by far to employ a treatment that prevents many of the virus’s deadly maladies. I’m still looking for more good management techniqurs

  2. Health
    Research Shows Drug Reduces COVID Infection by Up to 70% – Already FDA Approved for Cholesterol
    By University of Birmingham on Aug 12, 2021
    Beating COVID-19 Coronavirus
    Study reveals that a drug, which is approved for use by most countries in the world including the US Food and Drug Administration (FDA) and the UK’s National Institute for Health and Care Excellence (NICE), could reduce SARS-CoV-2 infection by up to 70 percent.

    A licensed drug normally used to treat abnormal levels of fatty substances in the blood could reduce infection caused by SARS-CoV-2 (the virus that causes COVID-19) by up to 70 percent, reveals a study in the laboratory by an international collaboration of researchers.

    The research team, led by the University of Birmingham and Keele University in the UK and the San Raffaele Scientific Institute in Italy, has demonstrated that fenofibrate and its active form (fenofibric acid) can significantly reduce SARS-COV-2 infection in human cells in the laboratory. Importantly, reduction of infection was obtained using concentrations of the drug which are safe and achievable using the standard clinical dose of fenofibrate. Fenofibrate, which is approved for use by most countries in the world including the US Food and Drug Administration (FDA) and the UK’s National Institute for Health and Care Excellence (NICE), is an oral drug currently used to treat conditions such as high levels of cholesterol and lipids (fatty substances) in the blood.

  3. The team is now calling for clinical trials to test the drug in hospitalized COVID-19 patients, to be carried out in addition to two clinical trials also currently underway in such patients in research being led by the Hospital of the University of Pennsylvania in the US and Hebrew University of Jerusalem in Israel.

    SARS-CoV-2, the virus that causes COVID-19, infects the host through an interaction between the Spike protein on the surface of the virus and the ACE2 receptor protein on host cells. In this study, responding to the global COVID-19 pandemic, the team tested a panel of already licensed drugs – including fenofibrate – to identify candidates that disrupt ACE2 and Spike interactions. Having identified fenofibrate as a candidate, they then tested the efficacy of the drug in reducing infection in cells in the laboratory using the original strains of the SARS-CoV-2 virus isolated in 2020. They found fenofibrate reduced infection by up to 70%. Additional unpublished data also indicates that fenofibrate is equally effective against the newer variants of SARS-CoV-2 including the alpha and beta variants and research is ongoing into its efficacy in the delta variant.

  4. Reference: “The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models” by Scott P. Davies, Courtney J. Mycroft-West, Isabel Pagani, Harriet J. Hill, Yen-Hsi Chen, Richard Karlsson, Ieva Bagdonaite, Scott E. Guimond, Zania Stamataki, Marcelo Andrade De Lima, Jeremy E. Turnbull, Zhang Yang, Elisa Vicenzi, Mark A. Skidmore, Farhat L. Khanim6 and Alan Richardson, 6 August 2021, Frontiers in Pharmacology.
    DOI: 10.3389/fphar.2021.660490

    The research, published on August 6, 2021, in Frontiers in Pharmacology, was also carried out in collaboration with the University of Copenhagen in Denmark and the University of Liverpool in the UK.